{"id":"https://openalex.org/W2000248717","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","title":"The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine","display_name":"The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine","publication_year":1996,"publication_date":"1996-11-01","ids":{"openalex":"https://openalex.org/W2000248717","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","mag":"2000248717","pmid":"https://pubmed.ncbi.nlm.nih.gov/8951192"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.1996.tb00055.x","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1996.tb00116.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1996.tb00116.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022136918","display_name":"Eric Snoeck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","NL"],"is_corresponding":true,"raw_author_name":"E. SNOECK","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031743563","display_name":"Philippe Jacqmin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"P. JACQMIN","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109551188","display_name":"A. Van Peer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"A. VAN PEER","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033133140","display_name":"Meindert Danhof","orcid":"https://orcid.org/0000-0002-2319-6830","observed_orcids":["https://orcid.org/0000-0002-2319-6830"]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"M. DANHOF","raw_affiliation_strings":["Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109106083","display_name":"Kris Ver Donck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"K. VER DONCK","raw_affiliation_strings":["Department of Biochemistry, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031824382","display_name":"Herman Van Belle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"H. VAN BELLE","raw_affiliation_strings":["Department of Scientific Support, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Scientific Support, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109910846","display_name":"Robert\u00a0J. H. Woestenborghs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"R. WOESTENBORGHS","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110158105","display_name":"Raf Crabb\u00e9","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","NL"],"is_corresponding":false,"raw_author_name":"R. CRABB\u00c9","raw_affiliation_strings":["Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063535372","display_name":"Renilt van Gool","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","NL"],"is_corresponding":false,"raw_author_name":"R. VAN GOOL","raw_affiliation_strings":["Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058611157","display_name":"Alain G. Dupont","orcid":"https://orcid.org/0000-0002-2918-9703","observed_orcids":["https://orcid.org/0000-0002-2918-9703"]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","NL"],"is_corresponding":false,"raw_author_name":"A. DUPONT","raw_affiliation_strings":["Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I137982388"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113762920","display_name":"J. Heykants","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"J. HEYKANTS","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5022136918"],"corresponding_institution_ids":["https://openalex.org/I121797337","https://openalex.org/I137982388"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":0.5982,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.69123278,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"42","issue":"5","first_page":"605","last_page":"613"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.2842000126838684,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.2842000126838684,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.20430000126361847,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.17679999768733978,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nucleoside-transport-inhibitors","display_name":"nucleoside transport inhibitors","score":0.859000027179718},{"id":"https://openalex.org/keywords/nonlinear-pharmacokinetics","display_name":"nonlinear pharmacokinetics","score":0.8460000157356262},{"id":"https://openalex.org/keywords/nucleoside-transporters","display_name":"nucleoside transporters","score":0.7369999885559082},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.5960000157356262},{"id":"https://openalex.org/keywords/binding-capacity","display_name":"binding capacity","score":0.4880000054836273},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.6610000133514404},{"id":"https://openalex.org/keywords/whole-blood-concentration","display_name":"whole blood concentration","score":0.48399999737739563},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.4729999899864197},{"id":"https://openalex.org/keywords/erythrocytes","display_name":"erythrocytes","score":0.6129999756813049},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.35100001096725464},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.7760000228881836},{"id":"https://openalex.org/keywords/sigmoidal-emax-model","display_name":"sigmoidal Emax model","score":0.7950000166893005},{"id":"https://openalex.org/keywords/binding-constant","display_name":"binding constant","score":0.3700000047683716},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8310470581054688},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.747868001461029},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6243832111358643},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.5059844851493835},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4109404981136322},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4014820158481598},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1289253532886505}],"mesh":[{"descriptor_ui":"D000241","descriptor_name":"Adenosine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004912","descriptor_name":"Erythrocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D033703","descriptor_name":"Nucleoside Transport Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/j.1365-2125.1996.tb00055.x","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1996.tb00116.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"doi:10.1111/j.1365-2125.1996.tb00116.x","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00116.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1996.tb00116.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1996.tb00116.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:8951192","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8951192","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:vubissmart:VUBISSMART:2000:48789","doi":null,"is_oa":false,"landing_page_url":"https://biblio.vub.ac.be/vubir/the-implications-of-nonlinear-red-blood-cell-partitioning-for-the-pharmacokinetics-and-pharmacodynamics-of-the-nucleoside-transport-inhibitor-draflazine(201fb610-c6f1-4f97-aef1-bcff71b2cfc9).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306402573","display_name":"VUBIR (Vrije Universiteit Brussel)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I13469542","host_organization_name":"Vrije Universiteit Brussel","host_organization_lineage":["https://openalex.org/I13469542"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2125.1996.tb00055.x","doi":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1996.tb00055.x","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1996.tb00116.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2000248717.pdf","grobid_xml":"https://content.openalex.org/works/W2000248717.grobid-xml"},"referenced_works_count":36,"referenced_works":["https://openalex.org/W1969611462","https://openalex.org/W1970391510","https://openalex.org/W1970592808","https://openalex.org/W1975785820","https://openalex.org/W1976573800","https://openalex.org/W1983649348","https://openalex.org/W1991869406","https://openalex.org/W1995656922","https://openalex.org/W1997876761","https://openalex.org/W1998746287","https://openalex.org/W2012491715","https://openalex.org/W2013276920","https://openalex.org/W2014420443","https://openalex.org/W2042074431","https://openalex.org/W2042399844","https://openalex.org/W2042784970","https://openalex.org/W2055351382","https://openalex.org/W2062151693","https://openalex.org/W2066342049","https://openalex.org/W2068862347","https://openalex.org/W2069081108","https://openalex.org/W2069533120","https://openalex.org/W2073199636","https://openalex.org/W2078865702","https://openalex.org/W2079265669","https://openalex.org/W2083780015","https://openalex.org/W2086032237","https://openalex.org/W2120765078","https://openalex.org/W2326663964","https://openalex.org/W2396453915","https://openalex.org/W2410538282","https://openalex.org/W2413552196","https://openalex.org/W2414743756","https://openalex.org/W2502670554","https://openalex.org/W2607461272","https://openalex.org/W2725806147"],"related_works":["https://openalex.org/W2070267141","https://openalex.org/W2068172192","https://openalex.org/W1592922204","https://openalex.org/W2008708115","https://openalex.org/W3129005669","https://openalex.org/W2471678155","https://openalex.org/W1989494948","https://openalex.org/W2314744659","https://openalex.org/W2910740134","https://openalex.org/W4238847870"],"abstract_inverted_index":{"1.":[0],"Draflazine,":[1],"a":[2,9,48,64,135,185,317,348],"nucleoside":[3,70,301,342],"transport":[4],"inhibitor,":[5],"was":[6,59,82,94,218,236,273],"administered":[7],"as":[8,47,63,347],"15":[10],"min":[11],"i.v.":[12],"infusion":[13],"of":[14,57,116,123,153,203,226,251,311,314,320,322],"2.5":[15],"mg":[16],"to":[17,30,37,68,101,112,299,329],"eight":[18],"healthy":[19],"male":[20],"subjects.":[21],"Plasma":[22],"and":[23,34,61,87,132,161,174,209,228,262,291,316],"whole":[24,268],"blood":[25,54,75,126,187,224,269,305,340],"concentrations":[26,246],"were":[27,35,127,171,255],"measured":[28,42],"up":[29],"32":[31],"h":[32],"post-dose,":[33],"related":[36],"adenosine":[38,331],"breakdown":[39,332],"inhibition":[40],"(ABI)":[41],"ex":[43,232,333],"vivo,":[44],"which":[45,99],"served":[46],"pharmacodynamic":[49,242,253,350],"endpoint.":[50],"2.":[51],"The":[52,77,121,139,191],"red":[53,74,186,304,339],"cell/plasma":[55],"distribution":[56,154,204],"draflazine":[58,124,227,315,326],"non-linear":[60,216],"characterized":[62,133,237],"capacity-limited":[65],"specific":[66,90,104],"binding":[67,78,91,105,110,189],"the":[69,73,88,117,221,229,239,252,271,300,312,323],"transporter":[71,302,324,343],"on":[72,245,303],"cells.":[76],"(dissociation)":[79],"constant":[80],"Kd":[81],"0.87":[83],"ng":[84,96,260,289],"ml-1":[85,97,261,290],"plasma":[86,170,182,196,222],"maximal":[89],"capacity":[92],"(Bmax)":[93],"164":[95],"RBC,":[98],"corresponds":[100],"about":[102],"14,000":[103],"sites":[106],"per":[107],"erythrocyte.":[108],"Non-specific":[109],"amounted":[111],"less":[113],"than":[114],"15%":[115],"total":[118],"binding.":[119],"3.":[120],"pharmacokinetics":[122,313],"in":[125,129,169,180,194,247,352],"determined":[128,178,231],"each":[130],"subject":[131],"by":[134,238,325],"two-compartment":[136],"pharmacokinetic":[137,140,192],"model.":[138,243],"parameters":[141,193,254],"(mean":[142,278],"+/-":[143,148,158,165,279,283,287,295],"s.d.)":[144,280],"were:":[145,197],"clearance":[146,198],"22.0":[147],"8.0":[149],"ml":[150,200],"mm-1,":[151],"volume":[152,202],"at":[155,205],"steady-state":[156,206],"39.8":[157],"4.7":[159],"l":[160,208],"terminal":[162,210],"half-life":[163,211],"24.0":[164],"9.4":[166],"h.":[167,213],"Concentrations":[168],"much":[172,274],"lower,":[173],"could":[175],"only":[176],"be":[177],"accurately":[179],"pooled":[181,195,248],"samples":[183],"with":[184,276,356],"cell":[188,341],"assay.":[190],"551":[199],"min-1,":[201],"349":[207],"10.7":[212],"4.":[214],"A":[215],"relationship":[217,235,272],"observed":[219],"between":[220],"or":[223],"concentration":[225],"ABI":[230],"vivo.":[233,334],"This":[234],"sigmoidal":[240],"Emax":[241,256,281],"Based":[244],"plasma,":[249],"values":[250,277],"100%,":[257],"IC50":[258,285],"10.5":[259],"Hill":[263,292],"factor":[264,293],"0.9.":[265,296],"When":[266],"using":[267],"concentrations,":[270],"steeper":[275],"92.4":[282],"5.6%,":[284],"76.0":[286],"15.3":[288],"3.5":[294],"5.":[297],"Binding":[298],"cells":[306],"is":[307,327,336],"an":[308],"important":[309],"determinant":[310],"high":[318],"degree":[319],"occupancy":[321,344],"required":[328],"inhibit":[330],"It":[335],"suggested":[337],"that":[338],"may":[345],"serve":[346],"useful":[349],"endpoint":[351],"dose":[353],"ranging":[354],"studies":[355],"draflazine.":[357]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}